Business Wire

PharmaJet Tropis Intradermal Delivery System is Now Authorized for Two Nucleic Acid Vaccines

First human DNA vaccine First in class thermostable self-amplifying mRNA vaccine GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company engineering precision delivery systems that overcome challenges ...
Morningstar

Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care

Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in ...
Morningstar

PharmaJet® to Present Latest Results of its Intradermal Programs at American Society of Tropical Medicine and Hygiene Annual Meeting

PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and ...
Business Wire

PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia

PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data reinforces how increased coverage, ...
ascopubs.org

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis. INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus ...